AU2003228819A8 - Combinations for the treatment of inflammatory skin disorders - Google Patents

Combinations for the treatment of inflammatory skin disorders

Info

Publication number
AU2003228819A8
AU2003228819A8 AU2003228819A AU2003228819A AU2003228819A8 AU 2003228819 A8 AU2003228819 A8 AU 2003228819A8 AU 2003228819 A AU2003228819 A AU 2003228819A AU 2003228819 A AU2003228819 A AU 2003228819A AU 2003228819 A8 AU2003228819 A8 AU 2003228819A8
Authority
AU
Australia
Prior art keywords
combinations
treatment
skin disorders
inflammatory skin
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003228819A
Other versions
AU2003228819A1 (en
Inventor
Nicole Hurst
M James Nichols
Grant R Zimmermann
Edward Roydon Jost-Price
Benjamin A Auspitz
Palaniyandi Manivasakam
Jason Fong
Curtis Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zalicus Inc
Original Assignee
CombinatoRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CombinatoRx Inc filed Critical CombinatoRx Inc
Publication of AU2003228819A1 publication Critical patent/AU2003228819A1/en
Publication of AU2003228819A8 publication Critical patent/AU2003228819A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003228819A 2002-05-03 2003-05-02 Combinations for the treatment of inflammatory skin disorders Abandoned AU2003228819A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37747502P 2002-05-03 2002-05-03
US60/377,475 2002-05-03
PCT/US2003/013760 WO2003092617A2 (en) 2002-05-03 2003-05-02 Combinations for the treatment of inflammatory skin disorders

Publications (2)

Publication Number Publication Date
AU2003228819A1 AU2003228819A1 (en) 2003-11-17
AU2003228819A8 true AU2003228819A8 (en) 2003-11-17

Family

ID=29401503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003228819A Abandoned AU2003228819A1 (en) 2002-05-03 2003-05-02 Combinations for the treatment of inflammatory skin disorders

Country Status (3)

Country Link
US (1) US20060100181A1 (en)
AU (1) AU2003228819A1 (en)
WO (1) WO2003092617A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053613A2 (en) * 2003-11-26 2005-06-16 Combinatorx, Inc. Combinations for the treatment of fungal infections
AU2005224160A1 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
US8980930B2 (en) 2004-06-25 2015-03-17 The Johns Hopkins University Angiogenesis inhibitors
SE0402029D0 (en) * 2004-08-17 2004-08-17 Synphora Ab Prostaglandin and a derivative for the treatment of psoriasis
CA2578999A1 (en) * 2004-09-01 2006-03-16 Trustees Of Boston University Use of thyroid hormone conversion inhibitors
BRPI0609361A2 (en) 2005-04-13 2010-03-30 Astion Pharma As use of a beta2 adrenoceptor agonist and dermatologically administrable pharmaceutical composition comprising said agonist
WO2007023841A1 (en) * 2005-08-25 2007-03-01 Taisho Pharmaceutical Co., Ltd. Hair growth agent composition
WO2009015366A2 (en) * 2007-07-26 2009-01-29 Trustees Of Boston University Use of thyroid hormone conversion inhibitors to treat hyperproliferative disorders
WO2010014263A1 (en) 2008-08-01 2010-02-04 Arca Discovery, Inc. Methods and compositions involving (s)-bucindolol
KR20120031954A (en) * 2009-05-27 2012-04-04 수캄포 아게 Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
HUP1000284A3 (en) * 2010-06-01 2012-08-28 Avidin Kft Use of derivatives of pgf1-alpha for preparation of medicament for reducing inflammation
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
CN110151591A (en) 2012-10-09 2019-08-23 宝洁公司 The method of identification collaboration cosmetic combinations
CN104704362B (en) 2012-10-09 2018-08-28 宝洁公司 The method of benefit active and the composition comprising it are assessed in identification
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
WO2017007799A1 (en) * 2015-07-07 2017-01-12 Grimes Pearl E TOPICAL TREATMENT REGIMENS CONTAINING A PROSTAGLANDIN F2α ANALOG AND A TOPICAL STEROID
WO2017037663A1 (en) 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids
CA3018316C (en) * 2016-03-30 2021-02-16 Daiichi Sankyo Company, Limited Griseofulvin compound
CN109394704B (en) * 2018-11-27 2021-09-17 西安力邦肇新生物科技有限公司 Prostaglandin E1 methyl ester freeze-dried preparation for injection and preparation and application thereof
CN109288848A (en) * 2018-11-27 2019-02-01 西安力邦肇新生物科技有限公司 Prostaglandin E1 methyl esters is preparing the application in vasodilator drug
KR102336218B1 (en) * 2019-02-26 2021-12-09 한국생명공학연구원 Composition for treating allergic skin disease or skin pruritis comprising colchicine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3729568A (en) * 1969-09-23 1973-04-24 Johnson & Johnson Acne treatment
US3899580A (en) * 1972-06-30 1975-08-12 Merck & Co Inc Anti-inflammatory topical gel
US4107306A (en) * 1973-01-16 1978-08-15 The Regents Of The University Of Michigan Process for treating proliferative skin disease
US4009282A (en) * 1973-12-17 1977-02-22 The Regents Of The University Of Michigan Treatment of proliferating skin diseases with prostaglandins
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4012508A (en) * 1975-02-03 1977-03-15 Burton Verna M Topical composition and method
US4201788A (en) * 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US4083974A (en) * 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4610978A (en) * 1983-03-22 1986-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
US5015481A (en) * 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
SE9403158D0 (en) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery

Also Published As

Publication number Publication date
AU2003228819A1 (en) 2003-11-17
US20060100181A1 (en) 2006-05-11
WO2003092617A2 (en) 2003-11-13
WO2003092617A3 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003286567A8 (en) Methods for the treatment of skin disorders
IL159771A0 (en) Combinations for the treatment of inflammatory disorders
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
SI1474416T1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
IL181706A0 (en) The treatment of inflammatory disorders and pain
PL378108A1 (en) Combination therapy for the treatment of immunoinflammatory disorders
AU2003274342A8 (en) Compositions for the treatment of autoimmune disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
EP1611120A4 (en) Novel methods for the treatment of inflammatory diseases
AU2003293099A8 (en) Treatment of dna damage related disorders
GB0213869D0 (en) The treatment of pain
ZA200405853B (en) Use of adapalene for the treatment of dermatological disorders
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
EP1539100A4 (en) Composition and methods for the treatment of skin disorders
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
GB2388027B (en) Use of palatinose for the treatment of mental stress
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
GB0201025D0 (en) The treatment of degenerative diseases
AU2003252187A8 (en) Topical composition for the treatment of inflammatory conditions of the skin
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB0216097D0 (en) Treatment of proliferative disorders
GB0513413D0 (en) The treatment of inflammatory disorders and pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase